{"id":4100,"date":"2023-04-19T07:33:49","date_gmt":"2023-04-19T07:33:49","guid":{"rendered":"https:\/\/founderlodge.com\/latest-news\/?p=4100"},"modified":"2023-04-19T07:33:50","modified_gmt":"2023-04-19T07:33:50","slug":"complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases","status":"publish","type":"post","link":"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/","title":{"rendered":"Complement Therapeutics Raises $78.9M in Series A Funding for Novel Therapeutics in Complement-Mediated Diseases"},"content":{"rendered":"<div class=\"wp-block-image\">\n<figure class=\"alignleft size-full\"><img decoding=\"async\" width=\"200\" height=\"200\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/admjhGcvb6T6bob1681830129.png\" alt=\"\" class=\"wp-image-4101\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/admjhGcvb6T6bob1681830129.png 200w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/admjhGcvb6T6bob1681830129-150x150.png 150w\" sizes=\"(max-width: 200px) 100vw, 200px\" \/><\/figure><\/div>\n\n\n<p>London-based biotechnology start-up<a href=\"https:\/\/complementtx.com\/\"> Complement Therapeutics (CTx)<\/a> has secured $78.9 million in Series A funding from investors. The Investors includes <a href=\"https:\/\/www.cic.vc\/\">Cambridge Innovation Capital<\/a>, <a href=\"https:\/\/www.gimv.com\/en\">Gimv<\/a>, <a href=\"https:\/\/forbion.com\/en\">Forbion<\/a>, <a href=\"https:\/\/seroba-lifesciences.com\/\">Seroba Life Sciences<\/a>, <a href=\"https:\/\/hadeanventures.com\/\">Hadean Venture<\/a>, <a href=\"http:\/\/www.panakes.it\/\">Panakes Partners<\/a>, and <a href=\"https:\/\/biogenerationventures.com\/en\/\">BGV (BioGeneration Ventures)<\/a>. CTx is focused on the research and development of novel therapeutics for complement-mediated diseases. They have a particular focus on dry age-related macular degeneration\/geographic atrophy, a leading cause of blindness.<\/p>\n\n\n\n<p>CTx&#8217;s lead investigational product, CTx001, is being evaluated as a potential gene therapy for dry age-related macular degeneration\/geographic atrophy. In addition, the company has other programs in development to explore potential therapeutic opportunities in other complement-mediated conditions.<\/p>\n\n\n\n<p>One of the unique aspects of CTx is its Complement Precision Medicine (CPM) platform. It developed as a quantification methodology to enable precise diagnosis and monitoring of diseases related to the complement cascade. The platform has the potential to quantify over 30 complement cascade proteins. They provide valuable insights into disease progression and treatment efficacy.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"449\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/Screenshot-157-1024x449.png\" alt=\"The team of Complement Therapeutics\" class=\"wp-image-4102\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/Screenshot-157-1024x449.png 1024w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/Screenshot-157-300x132.png 300w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/Screenshot-157-768x337.png 768w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/Screenshot-157.png 1334w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The funding raised in this Series A round will support CTx in advancing its research and development efforts, furthering its pipeline of novel therapeutics, and expanding its CPM platform. <\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"458\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/Screenshot-158-1024x458.png\" alt=\"About the complement therapeutics\" class=\"wp-image-4103\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/Screenshot-158-1024x458.png 1024w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/Screenshot-158-300x134.png 300w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/Screenshot-158-768x343.png 768w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/Screenshot-158.png 1329w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>CTx aims to make a significant impact in the field of complement-mediated diseases and improve the lives of patients suffering from these conditions.<\/p>\n\n\n\n<p>For more information on Complement Therapeutics and its research and development efforts, visit their Latest funding round at <a href=\"https:\/\/founderlodge.com\/round\/Complement-Therapeutics-raises-78929000-Series-A-2023-04-18-Rafiq-Hasan-MTIyNjY\">https:\/\/founderlodge.com\/round\/Complement-Therapeutics-raises-78929000-Series-A-2023-04-18-Rafiq-Hasan-MTIyNjY<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>London-based biotechnology start-up Complement Therapeutics (CTx) has secured $78.9 million in Series A funding from investors. The Investors includes Cambridge Innovation Capital, Gimv, Forbion, Seroba Life Sciences, Hadean Venture, Panakes Partners, and BGV (BioGeneration Ventures). CTx is focused on the research and development of novel therapeutics for complement-mediated diseases. They have a particular focus on [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":4104,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"categories":[2],"tags":[679,394,553,681,680],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.2.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Complement Therapeutics Raises $78.9M in Series A Funding for Novel Therapeutics in Complement-Mediated Diseases - Founder Lodge Latest News<\/title>\n<meta name=\"description\" content=\"London-based biotechnology start-up Complement Therapeutics (CTx) has secured $78.9 million in Series A funding from investors. The Investors includes\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Complement Therapeutics Raises $78.9M in Series A Funding for Novel Therapeutics in Complement-Mediated Diseases - Founder Lodge Latest News\" \/>\n<meta property=\"og:description\" content=\"London-based biotechnology start-up Complement Therapeutics (CTx) has secured $78.9 million in Series A funding from investors. The Investors includes\" \/>\n<meta property=\"og:url\" content=\"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Founder Lodge Latest News\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-19T07:33:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-19T07:33:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/Screenshot-156.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1326\" \/>\n\t<meta property=\"og:image:height\" content=\"622\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Ayesha Kanwal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ayesha Kanwal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/\"},\"author\":{\"name\":\"Ayesha Kanwal\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/84b30b34a96b8f66e08acd79b29fc198\"},\"headline\":\"Complement Therapeutics Raises $78.9M in Series A Funding for Novel Therapeutics in Complement-Mediated Diseases\",\"datePublished\":\"2023-04-19T07:33:49+00:00\",\"dateModified\":\"2023-04-19T07:33:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\"},\"keywords\":[\"Complement Therapeutics\",\"funding from investors\",\"latest funding round\",\"Novel Therapeutics\",\"Sereis A Funding\"],\"articleSection\":[\"Daily Startup Funding News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/\",\"name\":\"Complement Therapeutics Raises $78.9M in Series A Funding for Novel Therapeutics in Complement-Mediated Diseases - Founder Lodge Latest News\",\"isPartOf\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#website\"},\"datePublished\":\"2023-04-19T07:33:49+00:00\",\"dateModified\":\"2023-04-19T07:33:50+00:00\",\"description\":\"London-based biotechnology start-up Complement Therapeutics (CTx) has secured $78.9 million in Series A funding from investors. The Investors includes\",\"breadcrumb\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/founderlodge.com\/latest-news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Complement Therapeutics Raises $78.9M in Series A Funding for Novel Therapeutics in Complement-Mediated Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#website\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/\",\"name\":\"Founder Lodge Latest News\",\"description\":\"Get the latest updates on funding rounds and investment news for startups and businesses. Stay informed on capital raising trends and who&#039;s raising capital.\",\"publisher\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/founderlodge.com\/latest-news\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\",\"name\":\"Founder Lodge\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Founder Lodge\"},\"image\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/84b30b34a96b8f66e08acd79b29fc198\",\"name\":\"Ayesha Kanwal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7657d62981ef50c7c94f042b91db49ad?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7657d62981ef50c7c94f042b91db49ad?s=96&d=mm&r=g\",\"caption\":\"Ayesha Kanwal\"},\"url\":\"https:\/\/founderlodge.com\/latest-news\/author\/aisha\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Complement Therapeutics Raises $78.9M in Series A Funding for Novel Therapeutics in Complement-Mediated Diseases - Founder Lodge Latest News","description":"London-based biotechnology start-up Complement Therapeutics (CTx) has secured $78.9 million in Series A funding from investors. The Investors includes","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/","og_locale":"en_US","og_type":"article","og_title":"Complement Therapeutics Raises $78.9M in Series A Funding for Novel Therapeutics in Complement-Mediated Diseases - Founder Lodge Latest News","og_description":"London-based biotechnology start-up Complement Therapeutics (CTx) has secured $78.9 million in Series A funding from investors. The Investors includes","og_url":"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/","og_site_name":"Founder Lodge Latest News","article_published_time":"2023-04-19T07:33:49+00:00","article_modified_time":"2023-04-19T07:33:50+00:00","og_image":[{"width":1326,"height":622,"url":"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/04\/Screenshot-156.png","type":"image\/png"}],"author":"Ayesha Kanwal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ayesha Kanwal","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/#article","isPartOf":{"@id":"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/"},"author":{"name":"Ayesha Kanwal","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/84b30b34a96b8f66e08acd79b29fc198"},"headline":"Complement Therapeutics Raises $78.9M in Series A Funding for Novel Therapeutics in Complement-Mediated Diseases","datePublished":"2023-04-19T07:33:49+00:00","dateModified":"2023-04-19T07:33:50+00:00","mainEntityOfPage":{"@id":"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/founderlodge.com\/latest-news\/#organization"},"keywords":["Complement Therapeutics","funding from investors","latest funding round","Novel Therapeutics","Sereis A Funding"],"articleSection":["Daily Startup Funding News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/","url":"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/","name":"Complement Therapeutics Raises $78.9M in Series A Funding for Novel Therapeutics in Complement-Mediated Diseases - Founder Lodge Latest News","isPartOf":{"@id":"https:\/\/founderlodge.com\/latest-news\/#website"},"datePublished":"2023-04-19T07:33:49+00:00","dateModified":"2023-04-19T07:33:50+00:00","description":"London-based biotechnology start-up Complement Therapeutics (CTx) has secured $78.9 million in Series A funding from investors. The Investors includes","breadcrumb":{"@id":"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/founderlodge.com\/latest-news\/complement-therapeutics-raises-78-9m-in-series-a-funding-for-novel-therapeutics-in-complement-mediated-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/founderlodge.com\/latest-news\/"},{"@type":"ListItem","position":2,"name":"Complement Therapeutics Raises $78.9M in Series A Funding for Novel Therapeutics in Complement-Mediated Diseases"}]},{"@type":"WebSite","@id":"https:\/\/founderlodge.com\/latest-news\/#website","url":"https:\/\/founderlodge.com\/latest-news\/","name":"Founder Lodge Latest News","description":"Get the latest updates on funding rounds and investment news for startups and businesses. Stay informed on capital raising trends and who&#039;s raising capital.","publisher":{"@id":"https:\/\/founderlodge.com\/latest-news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/founderlodge.com\/latest-news\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/founderlodge.com\/latest-news\/#organization","name":"Founder Lodge","url":"https:\/\/founderlodge.com\/latest-news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Founder Lodge"},"image":{"@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/84b30b34a96b8f66e08acd79b29fc198","name":"Ayesha Kanwal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7657d62981ef50c7c94f042b91db49ad?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7657d62981ef50c7c94f042b91db49ad?s=96&d=mm&r=g","caption":"Ayesha Kanwal"},"url":"https:\/\/founderlodge.com\/latest-news\/author\/aisha\/"}]}},"_links":{"self":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/4100"}],"collection":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/comments?post=4100"}],"version-history":[{"count":1,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/4100\/revisions"}],"predecessor-version":[{"id":4105,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/4100\/revisions\/4105"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/media\/4104"}],"wp:attachment":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/media?parent=4100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/categories?post=4100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/tags?post=4100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}